Xvivo Perfusion AB (publ) (XVIPY)
OTCMKTS · Delayed Price · Currency is USD
6.34
-0.20 (-3.06%)
Feb 4, 2026, 4:00 PM EST
Xvivo Perfusion AB Market Cap
Xvivo Perfusion AB has a market cap or net worth of $754.44 million as of February 6, 2026. Its market cap has decreased by -40.64% in one year.
Market Cap
754.44M
Enterprise Value
735.90M
Revenue
88.11M
Ranking
n/a
PE Ratio
276.35
Stock Price
$6.34
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 56.07M to 754.44M, an increase of 1,245.52%. That is a compound annual growth rate of 21.52%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 5, 2026 | 754.44M | 17.97% |
| Dec 30, 2025 | 639.52M | -54.14% |
| Dec 30, 2024 | 1.39B | 35.52% |
| Dec 29, 2023 | 1.03B | 96.50% |
| Dec 30, 2022 | 523.72M | -42.34% |
| Dec 30, 2021 | 908.22M | -17.47% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Veradigm | 790.56M |
| Glass House Brands | 753.35M |
| Northwest Biotherapeutics | 453.22M |
| Elite Pharmaceuticals | 446.31M |
| Nika Pharmaceuticals | 403.38M |
| American Oncology Network | 377.98M |
| CytoDyn | 308.99M |
| OpGen | 267.80M |